BioSpace News Archive

Protalix BioTherapeutics, Inc. today reported financial results for the fiscal year ended December 31, 2022 and provided a business update on recent corporate and regulatory developments.

Asensus Surgical, Inc. announced today that it plans to release fourth quarter and full year 2022 financial and operating results after the market closes on Thursday, March 2, 2023.

Humacyte, Inc. today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March.

Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference.

Neuboron Medical Group, a leading global Accelerator-based Boron Neutron Capture Therapy total solution provider announced that the first AB-BNCT cancer research center in China, Xiamen Humanity Hospital BNCT Center has successfully performed 14 irradiations on 12 patients for its first Investigator Initiated Trial aimed to evaluate the safety and efficacy of BNCT in the treatment of advanced refractory malignant tumors.

Dr. Reddy’s Laboratories SA today announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (ASX: MYX).

Viatris Inc. (NASDAQ: VTRS) today reported strong results for the fourth quarter and full year 2022, meeting its adjusted guidance range for 2022 after incorporating the fourth quarter impact of the closing of the transaction pursuant to which the Company contributed its biosimilars portfolio to Biocon Biologics (the “Biosimilars Transaction”) and acquired IPR&D.

InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn’s and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.

SpringWorks Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for nirogacestat.

BIOLASE, Inc. has launched a new e-commerce website for its U.S. customers.